Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Marker Therapeutics stock | $1.55

Own Marker Therapeutics stock in just a few minutes.

Fact checked

Marker Therapeutics, Inc is a biotechnology business based in the US. Marker Therapeutics shares (MRKR) are listed on the NASDAQ and all prices are listed in US Dollars. Marker Therapeutics employs 28 staff and has a trailing 12-month revenue of around USD$679,979.

How to buy shares in Marker Therapeutics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Marker Therapeutics. Find the stock by name or ticker symbol: MRKR. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Marker Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$1.55, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Marker Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Marker Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Marker Therapeutics share price

Use our graph to track the performance of MRKR stocks over time.

Marker Therapeutics shares at a glance

Information last updated 2020-12-01.
Latest market closeUSD$1.55
52-week rangeUSD$1.32 - USD$3.43
50-day moving average USD$1.5354
200-day moving average USD$1.8351
Wall St. target priceUSD$7
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-4.165

Buy Marker Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
$0 for US stocks
Stocks, Options, ETFs
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
TD Ameritrade
or $25 broker-assisted
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Marker Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Marker Therapeutics price performance over time

Historical closes compared with the close of $1.55 from 2020-12-09

1 week (2021-01-08) -13.41%
1 month (2020-12-15) -0.64%
3 months (2020-10-15) -0.64%
6 months (2020-07-15) -16.22%
1 year (2020-01-15) -49.35%
2 years (2019-01-15) -72.66%
3 years (2018-01-12) 3.61
5 years (2016-01-15) 202.44%

Marker Therapeutics financials

Revenue TTM USD$679,979
Gross profit TTM USD$-12,551,610
Return on assets TTM -32.18%
Return on equity TTM -64.42%
Profit margin 0%
Book value $0.637
Market capitalisation USD$81.6 million

TTM: trailing 12 months

Shorting Marker Therapeutics shares

There are currently 3.6 million Marker Therapeutics shares held short by investors – that's known as Marker Therapeutics's "short interest". This figure is 0.1% up from 3.6 million last month.

There are a few different ways that this level of interest in shorting Marker Therapeutics shares can be evaluated.

Marker Therapeutics's "short interest ratio" (SIR)

Marker Therapeutics's "short interest ratio" (SIR) is the quantity of Marker Therapeutics shares currently shorted divided by the average quantity of Marker Therapeutics shares traded daily (recently around 150277.68115942). Marker Therapeutics's SIR currently stands at 24.15. In other words for every 100,000 Marker Therapeutics shares traded daily on the market, roughly 24150 shares are currently held short.

However Marker Therapeutics's short interest can also be evaluated against the total number of Marker Therapeutics shares, or, against the total number of tradable Marker Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Marker Therapeutics's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 Marker Therapeutics shares in existence, roughly 80 shares are currently held short) or 0.1266% of the tradable shares (for every 100,000 tradable Marker Therapeutics shares, roughly 127 shares are currently held short).

A SIR above 20% would generally be considered very high, pointing to a pessimistic outlook for the share price, with a discouraging number of investors currently willing to bet against Marker Therapeutics.

Find out more about how you can short Marker Therapeutics stock.

Marker Therapeutics share dividends

We're not expecting Marker Therapeutics to pay a dividend over the next 12 months.

Have Marker Therapeutics's shares ever split?

Marker Therapeutics's shares were split on a 1:12 basis on 16 September 2016. So if you had owned 12 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Marker Therapeutics shares – just the quantity. However, indirectly, the new 1100% higher share price could have impacted the market appetite for Marker Therapeutics shares which in turn could have impacted Marker Therapeutics's share price.

Marker Therapeutics share price volatility

Over the last 12 months, Marker Therapeutics's shares have ranged in value from as little as $1.32 up to $3.43. A popular way to gauge a stock's volatility is its "beta".

MRKR.US volatility(beta: 1.17)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Marker Therapeutics's is 1.1657. This would suggest that Marker Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Marker Therapeutics overview

Marker Therapeutics, Inc., a clinical stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. Its MultiTAA-specific T cell technology is based on the expansion of non-engineered tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, multiple myeloma, and various solid tumors; and allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia. It is also developing TPIV100/110, which is in Phase II clinical trial to treat breast cancer; and TPIV200 that is in Phase II clinical trial for the treatment of breast and ovarian cancers. Marker Therapeutics, Inc. is headquartered in Houston, Texas.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site